RECRUITINGOBSERVATIONAL
New Biomarkers and Therapeutic Targets in Osteoporosis Via Omics Technologies
Identification of New Biomarkers and Potential Therapeutic Targets in Clinical Osteoporosis Using Omics Technologies
About This Trial
This study aims to discover novel biomarkers and therapeutic targets for osteoporosis through the use of advanced omics technologies, including proteomics and metabolomics. By analyzing bone and plasma samples from patients with osteoporosis, the research seeks to understand the underlying mechanisms of the disease and identify potential diagnostic and therapeutic biomarkers.
Who May Be Eligible (Plain English)
Who May Qualify:
- Postmenopausal Female Patients with osteoporotic subcapital femoral neck fracture (Arm 1)
- Postmenopausal Female Patients with hip osteoarthritis that will undergo Total Hip Replacement (Arm 2)
Who Should NOT Join This Trial:
- Patients that have undergone before osteoporotic fractures
- Patients with severe cardiovascular, pulmonary, autoimmune, or urinary system conditions
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Postmenopausal Female Patients with osteoporotic subcapital femoral neck fracture (Arm 1)
* Postmenopausal Female Patients with hip osteoarthritis that will undergo Total Hip Replacement (Arm 2)
Exclusion Criteria:
* Patients that have undergone before osteoporotic fractures
* Patients with severe cardiovascular, pulmonary, autoimmune, or urinary system conditions
Treatments Being Tested
OTHER
Bone, Serum and Plasma sample
Intervention: Bone samples will be collected during surgery from the femoral neck (which is typically removed and discarded in these operations) and fasting morning blood samples.
Locations (1)
Laboratory for Research of the Musculoskeletal System
Kifissia, Attica, Greece